In part one, Alan Wein is joined by Melissa Kaufman, who chaired the AUA Guideline Committee on Genitourinary Syndrome of Menopause (GSM), to discuss these guidelines. Dr. Kaufman emphasizes the ...

Zachary Klaassen hosts Andrew Hahn to discuss future directions in metastatic castration-resistant prostate cancer. Dr. Hahn highlights the "golden era" for targeting cell surface proteins through ...

Developing effective strategies to prevent biofilm formation on urinary catheter surfaces is critical for reducing catheter-associated urinary tract infections (CAUTIs) in clinical settings. In this ...

psa nadir 0.2, metastatic hormone sensitive prostate cancer, mHSPC treatment, PSA targets prostate cancer, PSA Thresholds in mHSPC: What VA Data Reveals About Optimal Targets with Stephen Freedland, ...

Over the past decade, the availability of Prostate-specific membrane antigen-directed PET (PSMA-PET) for staging and restaging of prostate cancer has expanded considerably worldwide. Compared to ...

CHAI biomarker, using AI to predict BCG vs Gem/Doce response in bladder cancer, achieving 90% success rate, insights on precision medicine, Computational Histology AI Guides Treatment Selection for ...

Evan Yu is joined by Atish Choudhury to discuss a first-in-human trial combining EZH2 and PARP inhibition in metastatic castration-resistant prostate cancer. Dr. Choudhury explains that EZH2 is an ...

Current prognostic assessment of men with biochemical recurrence(BCR) after radical prostatectomy(RP) relies on data from the pre-2000s era when androgen deprivation therapy(ADT) was delayed until ...

In [18F]F-PSMA-1007 PET imaging, focal bone uptake without morphological correlate (MC) on CT, is often classified as benign. In [68Ga]Ga-PSMA-11, intense focal uptake without MC in a classical ...

Trimodality therapy (TMT), consisting of maximal transurethral resection of bladder tumor (TURBT) followed by concurrent chemoradiotherapy, has emerged as a bladder-sparing alternative to radical ...

Leslie Ballas speaks with Timothy Showalter about a multimodal artificial intelligence-based prostate cancer test. Dr. Showalter explains how ArteraAI analyzes H&E-stained biopsy slides using computer ...

PDIGREE phase III adaptive, enrolled 1000+ metastatic kidney cancer patients across 500+ sites, ASCO 2025 results and innovative treatment strategies, PDIGREE Trial Tests Adaptive Immunotherapy ...